AstraZeneca IMFINZI Shows Unprecedented Survival in Unresectable Stage III Lung Cancer

 

With 43% Of Patients Surviving Five Years

Long-term data from PACIFIC Phase III trial at ASCO showed 33% of patients remained progression-free at five years

Longest-ever survival reported in a Phase III immunotherapy trial in this setting

https://finance.yahoo.com/news/imfinzi-demonstrated-unprecedented-survival-unresectable-110000358.html